Array
(
    [site_id] => 154
    [page_id] => 470
    [parent_page_id] => 
    [organization_id] => 262
    [pageOrder] => 0
    [position] => 
    [block_ids] => Array
        (
            [0] => 2010
            [1] => 2012
            [2] => 2015
            [3] => 2058
            [4] => 2016
            [5] => 2117
            [6] => 2007
            [7] => 2011
        )

    [_thumbnail_id] => 29
)



Array
(
    [id] => 262
    [uuid] => 2aeba289-4ba7-4a7f-bd79-2d38acac0eee
    [ownerId] => 318
    [name] => Hemab
    [slug] => hemab
    [organizationUrl] => https://hemab.com/
    [privacyPolicyUrl] => https://hemab.com/#privacy-policy
    [primaryContactFirstName] => 
    [primaryContactLastName] => 
    [primaryContactEmail] => 
    [customerId] => cus_NM31FmVZ1ME3Lt
    [subscriptionId] => sub_1MbKvZF0UYZu1VXYiP6BbY08
    [createdAt] => 2023-02-14T09:35:55.195Z
    [updatedAt] => 2023-03-08T09:07:25.470Z
)



Array
(
    [buttonActions] => Array
        (
            [primaryButtonAction] => 
            [secondaryButtonAction] => 
        )

    [id] => 2010
    [type] => header
    [listType] => 
    [blockOrder] => 0
    [title] => Become a part of Hemab
    [subTitle] => Join us as we work together to give patients with rare clotting disorder a new lifeline and improve health equity around the globe.
    [body] => 
    [backgroundType] => video
    [backgroundPattern] => 
    [backgroundColor] => transparent
    [backgroundVideo] => 800495740
    [blockSize] => sm
    [paddingVertical] => md
    [imageLeft] => 1
    [primaryButtonAction] => 
    [secondaryButtonAction] => 
    [contactName] => 
    [contactEmail] => 
    [createdAt] => 2023-02-14T09:36:01.114Z
    [updatedAt] => 2023-02-20T12:15:35.501Z
    [pageId] => 470
    [organizationId] => 262
    [files] => Array
        (
            [0] => Array
                (
                    [id] => 19112
                    [uuid] => a0934bb8-2e7d-4748-8a01-f06b13eaacbe
                    [filename] => Hemab_Header.jpg
                    [type] => image
                    [docType] => other
                    [mimeType] => image/jpeg
                    [bucketKey] => 2aeba289-4ba7-4a7f-bd79-2d38acac0eee/a0934bb8-2e7d-4748-8a01-f06b13eaacbe/Hemab_Header.jpg
                    [alt] => 
                    [public] => 1
                    [isCp] => 1
                    [temp] => 
                    [createdAt] => 2023-02-15T13:17:19.560Z
                    [updatedAt] => 2023-02-15T13:17:34.352Z
                    [brandingId] => 
                    [blockId] => 2010
                    [organizationId] => 262
                    [positionId] => 
                    [applicationId] => 
                )

        )

)



Array
(
    [0] => Array
        (
            [id] => 19112
            [uuid] => a0934bb8-2e7d-4748-8a01-f06b13eaacbe
            [filename] => Hemab_Header.jpg
            [type] => image
            [docType] => other
            [mimeType] => image/jpeg
            [bucketKey] => 2aeba289-4ba7-4a7f-bd79-2d38acac0eee/a0934bb8-2e7d-4748-8a01-f06b13eaacbe/Hemab_Header.jpg
            [alt] => 
            [public] => 1
            [isCp] => 1
            [temp] => 
            [createdAt] => 2023-02-15T13:17:19.560Z
            [updatedAt] => 2023-02-15T13:17:34.352Z
            [brandingId] => 
            [blockId] => 2010
            [organizationId] => 262
            [positionId] => 
            [applicationId] => 
        )

)
BLOCK FILES UUID: a0934bb8-2e7d-4748-8a01-f06b13eaacbeAttachment Title: aa2ad783-115e-4bfd-abbb-d09db968229e


Attachment Title: 8e0e1663-a7f5-4d4a-899b-fc754529b578


Attachment Title: 44cd4df0-c8b6-49b8-932e-4d1d437aedcf


Attachment Title: 24e78683-8600-4df9-9cfa-6ecfcf2eb0f0


Attachment Title: b5b7babc-3910-4e43-bd69-3b73b909787d


Attachment Title: 780eaa57-cfcf-4123-a8a6-d381423258f7


Attachment Title: dfcf9106-9185-488e-99c1-2fc0b0335c8a


Attachment Title: 266c0756-f906-41d8-ba78-c4dee4df9054


Attachment Title: 696cb3ed-2a54-4132-a1f1-4dd3517a4d64


Attachment Title: 64e0ef8c-76a9-492a-a443-3362321f11b9


Attachment Title: a39b467c-5fa6-4221-ac68-60afa52f77d1


Attachment Title: f824d8e3-6057-46dd-8bd7-588debaf6dda


Attachment Title: 36a7d8f6-3727-46d2-953c-ecbff87e657a


Attachment Title: 88210a5d-f02d-4c27-bd1a-bec71b39ccbc


Attachment Title: aa37b036-2e4a-4219-a6b4-25b22e98f0b9


Attachment Title: e8ff4007-a32f-4f0a-ab31-5da008dc2280


Attachment Title: 0c666605-6b81-48ee-bded-864fa236edfc


Attachment Title: d0f5a8ab-87fa-451d-b68a-90dcbebae0a5


Attachment Title: 1655b26b-008f-4668-adc2-0c03782502c2


Attachment Title: 2b60b1e1-0fcc-4556-bc33-c36427b8b47f


Attachment Title: 8ccbb4c6-f4d4-43d6-9cb7-155f0eb2bfc6


Attachment Title: 7a3d418e-4de3-459b-a677-d209e206fa01


Attachment Title: 6cbd72ee-bcfa-4259-885c-74d6631b506d


Attachment Title: 2a39fce4-9d34-4ce8-9eab-f2236625ab67


Attachment Title: c3d5794d-4ded-4521-ad39-3e52bfad82c6


Attachment Title: ced9f046-6207-42d2-83fc-b701fb7f5724


Attachment Title: 4705bfd8-c420-4567-965d-6e24f90652f5


Attachment Title: aea53ed4-1198-4636-b542-0e9fd2443110


Attachment Title: 46db73a5-cd01-4eb1-8486-4b63166f79fb


Attachment Title: 60b9ca0c-2565-4364-b969-f3cd950c1f90


Attachment Title: 1cc78454-c56c-4a52-9d5a-9ba9ca746b80


Attachment Title: b1228b34-76c3-4309-ab54-f67ccb046d27


Attachment Title: 69f4cf23-0b9b-4696-8bfd-3335bd474f5e


Attachment Title: 9c80bce2-0d7c-471b-ab21-ff5026be27f4


Attachment Title: 9917ea74-1ab0-4018-a8b0-19c609243f48


Attachment Title: b95e4578-0ecc-4dc2-b9f2-c14346340a6b


Attachment Title: 1e482ed6-25ee-4ac9-836f-b12b115b345f


Attachment Title: 09a7cf2e-2fdd-4539-9240-06c607e230a6


Attachment Title: a0934bb8-2e7d-4748-8a01-f06b13eaacbe


Attachment Title: d41e486f-dafb-4f70-9373-2c590204018d

Become a part of Hemab

Join us as we work together to give patients with rare clotting disorder a new lifeline and improve health equity around the globe.

About Hemab

Hemab is pioneering the first targeted preventative treatments and functional cures for underserved bleeding and thrombotic disorders - reimagining the standard of care for patients everywhere.

We are a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, MA, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need.

Join the ultimate clotting company

While patients with common bleeding and thrombotic disorders have had access to preventative treatments for more than a half-century, no such measures exist for less-common disorders. For these tens of thousands of women, men and children, life is paralyzingly unpredictable.

A bleeding or thrombotic event can strike any moment, from a simple menstrual period to a routine dental procedure, and cause symptoms so severe that by the time they reach a hospital, it may be too late. It’s time to ensure that every clotting disorder patient has the security and peace of mind they deserve.

Let’s build the ultimate clotting company together!

Our mission

Hemab Therapeutics is pioneering preventative treatments for a full spectrum of underserved bleeding and thrombotic disorders. Building on validated technologies to introduce new prophylactic therapies for patients with genetic inabilities to form clots, Hemab is ensuring that no patient of a blood clotting disorder is ever left behind. 

Our teams are global, diverse, and committed to collaboration, excellent research, and swift development of our potential therapies.